Harrow is a North American ophthalmic disease management company that develops, acquires, and commercializes FDA-approved medications and therapies for eye conditions including dry eye disease, age-related macular degeneration, glaucoma, and retinal diseases. The company generates revenue through three primary channels: branded pharmaceutical products (including over 15 marketed drugs and biosimilars addressing anterior and posterior segment diseases), custom pharmaceutical compounding through its ImprimisRx facilities, and a development pipeline of late-stage candidates. Harrow serves U.S. ophthalmologists, optometrists, ambulatory surgery centers, hospitals, and healthcare systems, with revenues dependent on reimbursement from Medicare, Medicaid, private insurers, and pharmacy benefit managers, while also distributing internationally through partnerships and leveraging intellectual property including 50+ issued or pending patents.